These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9686611

  • 1. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J, Heirman C, de Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K.
    J Immunol; 1998 Aug 01; 161(3):1454-61. PubMed ID: 9686611
    [Abstract] [Full Text] [Related]

  • 2. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 3. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H, Thielemanns K, Tesch H, Engert A, Wolf HJ, van Camp B, Urbain J, Diehl V.
    Cytokines Mol Ther; 1996 Dec 01; 2(4):231-8. PubMed ID: 9384709
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C, Brissinck J, De Jonge J, Thielemans K.
    J Hematother; 1995 Oct 01; 4(5):363-8. PubMed ID: 8581370
    [Abstract] [Full Text] [Related]

  • 10. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M.
    Cancer Res; 2000 Aug 15; 60(16):4336-41. PubMed ID: 10969772
    [Abstract] [Full Text] [Related]

  • 11. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J, Demanet C, Moser M, Leo O, Thielemans K.
    J Immunol; 1991 Dec 01; 147(11):4019-26. PubMed ID: 1940384
    [Abstract] [Full Text] [Related]

  • 12. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
    Penna C, Dean PA, Nelson H.
    Cancer Res; 1994 May 15; 54(10):2738-43. PubMed ID: 8168104
    [Abstract] [Full Text] [Related]

  • 13. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P.
    J Immunol; 1997 Apr 15; 158(8):3965-70. PubMed ID: 9103467
    [Abstract] [Full Text] [Related]

  • 14. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
    Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.
    J Mol Biol; 2010 Jun 11; 399(3):436-49. PubMed ID: 20382161
    [Abstract] [Full Text] [Related]

  • 15. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 16. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H.
    Cancer Res; 1997 May 01; 57(9):1704-9. PubMed ID: 9135012
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Biologic activity of bispecific single chain antibody against human gamma-seminoprotein and CD3 molecule].
    Wang D, Wang H, Wu GJ, Wu WZ, Yang SL, Lin WH, Tan JM.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul 01; 22(4):500-3. PubMed ID: 16806016
    [Abstract] [Full Text] [Related]

  • 20. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Jul 01; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.